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1. Introduction 
Breast cancer is the most common cancer in women, with more than 1,000,000 new cases and 
more than 410,000 deaths each year [38]; [39]. At present, breast cancer is mainly treated by 
surgical therapy as well as cytotoxic, hormonal and immunotherapeutic agents. These 
methods achieve response rates ranging from 60 to 80% for primary breast cancers and about 
50% of metastases [22]; [24]. However, up to 20 to 70% of patients relapse within 5 years [10]. 
The reason for recurrence is the existence of cancer stem cells in malignant tumors such 
brain, prostate, pancreatic, liver, colon, head and neck, lung and skin tumors [3]; [7]; [14]; 
[15]; [21]; [32]; [49]; [51]. Breast cancer stem cells (BCSCs) were first detected by Al-Hajj et al. 
(2003) that showed cells expressing CD44 protein and weakly or not expressing CD24 
protein could establish new tumors in xeno-grafted mice. Using these markers, researchers 
isolated BCSCs from primary [41]; [47] and established breast cancer cell lines [16]. Another 
technique used is cell culture in serum-free medium to form mammospheres. 
Mammospheres exhibit many stem cell-like properties such as differentiation into all three 
mammary epithelial lineages [11]; [12]. These BCSCs have been demonstrated to cause 
treatment resistance and relapse. Thus, BCSC-targeting therapy is considered a promising 
therapy for treating breast cancer. 
Recently, BCSC-targeting therapies have been researched by various groups worldwide. 
Strategies include targeting the self-renewal of BCSCs [30]; [31], indirectly targeting the 
microenvironment [29]; [50]; [31] and directly killing BCSCs by chemical agents that induce 
differentiation [25]; [19]; [42]; [43], immunotherapy [4]; [5]; [40] and oncolytic viruses [26]; [34]. 
In all strategies, isolation of BCSCs is an important step to recover starting materials for all 
subsequent steps. Thus, isolation of BCSCs is a pivotal step for successful outcomes. Almost all 
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studies have focused more on treatment strategies than isolation of BCSCs. Indeed, to date, 
there are only three methods used to identify and isolate BCSCs, namely fluorescence-activated 
cell sorting (FACS) based on BCSC markers such as CD44, CD24 and CD133 [2]; [52]; [46]; [41], 
identification of the side population (SP) that effluxes Hoechst 33342 [13]; [8]; [28] and 
mammosphere formation [44]; [54]. All these methods possess some limitations. 
The first limitation is the resulting heterogenous population of BCSCs. Using these 
techniques, the BCSC population contains phenotypes with differences in CD44 and CD24 
expression levels. These differences reflect variations in some cellular behaviors. BCSCs 
isolated by SP sorting or mammosphere culture may contain a small population that do not 
exhibit the CD44+CD24- phenotype. Thus, in this study, we attempted to establish a new 
method to isolate a homogenous population from malignant breast tumors.  
Our study is based on the cell cloning technique that is applied to select hybridomas for 
monoclonal antibody production. Using a cell sorter with the index sorting function, we aim 
establish a new protocol that can isolate and establish BCSC clones at a high efficiency.  
2. Materials and methods 
2.1. Primary culture 
Primary culture of breast cancer cells from malignant breast tumors was carried out as 
described elsewhere [41]; [42]. Tumor biopsies were obtained from consenting patients at 
the Oncology Hospital in Ho Chi Minh city, Vietnam, and then transferred to the laboratory 
on ice. All samples were kept in phosphate-buffered saline (PBS) containing 1× antibiotics 
and an antimycotic (Sigma-Aldrich, St Louis, MO). Tumors were homogenized into small 
fragments (approximately 1–2 mm3) using scissors. These samples were seeded in 35-mm 
culture dishes (Nunc, Roskilde, Denmark) in M171 medium (Invitrogen, Carlsbad, CA) 
containing mammary epithelial growth supplement (MEGS) (Invitrogen, Carlsbad, CA), and 
incubated at 37°C with 5% CO2. Five patients participated in this study.  
2.2. Single-cell sorting 
Primary cells were detached by 0.25% trypsin/EDTA. The cell suspension was washed twice 
with PBS to eliminate trypsin. The cell pellet was resuspended in sorting buffer (PBS 
containing 0.2 mM EDTA and 1 mg/mL bovine serum albumin (BSA) at 1x106 cells/ml. 
Single-cell sorting was performed on a BD FACSJazz (BD Bioscience, Franklin Lakes, NJ) 
using the index sorting function. One cell was sorted into one well of a 96-well plate that 
contained M171 medium with MEGS. One sample was sorted into 2880 wells in 30 plates. 
After sorting, all wells were checked for a single cell/well under an inverted microscope.  
2.3. Single cell-based culture and selection of mesenchymal-like cells 
After single-cell sorting, cells were cultured in M171 medium containing MEGS and incubated 
at 37°C with 5% CO2. Half medium volumes were exchanged every 3 days for 30 days. Then, 
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only wells that contained cell colonies were used to select mesenchymal-like cell clones by 
replacing M171 medium with DMEM/F12 supplemented 10% fetal bovine serum (FBS) for 2 
days. In this medium, all epithelial-like cells did not survive. Surviving mesenchymal-like cell 
clones were continuously subcultured for three to five passages. Cell clones that rapidly 
underwent an epithelial-mesenchymal transition (EMT) were considered as BCSC candidates. 
These cells were used to analyze some characteristics of BCSCs in subsequent experiments.  
2.4. CD44+CD24-/dim-based cell sorting  
BCSCs were isolated from primary cultures based on CD44+CD24- expression by FACS as 
described elsewhere [42]. Briefly, 1 ml cell suspensions in PBS (1x107 cells) were double 
stained with 20 μl anti-CD44-FITC and 20 μl anti-CD24-PE. Samples were incubated in the 
dark at room temperature for 45 min. The CD44+CD24-/dim cell population was identified 
by the software controlling the BD FACSJazz. Cells were sorted into 2-ml tubes containing 1 
ml culture medium (DMEM/F12 supplemented with 10% FBS and a 1× antibiotic-mycotic 
(Sigma-Aldrich, St Louis, MO).  
2.5. Rhodamine 123 efflux and SP analysis 
Cells were stained with 0.1 μg/mL rhodamine (Sigma-Aldrich) at 37°C for 30 min, and then 
washed twice with 2% FBS in PBS. Two filters (FL1 and FL3) were used to detect rhodamine 
123. Cells incubated with 50 μM verapamil and 0.1 μg/ml rhodamine 123 for 30 min were 
used as a positive control.  
2.6. Immunophenotyping 
Cell markers were analyzed following a previously published protocol [43]. Briefly, cells 
were washed twice in PBS containing 1% BSA (Sigma-Aldrich). Cells were stained for 30 
min at 4°C with anti-CD13-FITC, anti-CD90-PE and anti-CD133-PerCP monoclonal 
antibodies (BD Biosciences). Stained cells were analyzed by a BD FACSCalibur (BD 
Biosciences) flow cytometer. Isotype controls were used in all analyses.  
2.7. Mammosphere culture 
Cells were detached with 0.25% trypsin/EDTA and resuspended in serum-free DMEM/F12 
(1:1; GeneWorld, Ho Chi Minh, VN) containing 15 ng/ml basic fibroblast growth factor, 20 
ng/ml epidermal growth factor (EGF), 2 mM/l L-glutamine, 4 U/l insulin growth factor (Sigma-
Aldrich) and B27 supplement (1:50; Invitrogen). Cells were cultured at 37°C with 5% CO2. 
2.8. Cell cycle analysis 
Cells were washed twice in PBS and fixed in cold 70% ethanol for at least 3 h at 4°C. Then, 
cells were washed twice in PBS and stained with 1 ml PI (20 μg/ml). Fifty microliters of 
RNase A (10 μg/ml) was added to samples, followed by incubation for 3 h at 4°C. Stained 
cells were analyzed by flow cytometry using CellQuest Pro software (BD Biosciences). 
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2.9. Doxorubicin resistance analysis 
BCSCs were cultured to 104 cells/well in a 24-well plate (Nunc, Roskilde, Denmark), in 
DMEMF12/10% FBS. After 24 h culture to confluence, cells were treated with 0, 1 and 3 
μg/ml doxorubicin (Sigma-Aldrich). Doxorubicin resistance was analyzed by apoptosis 
using annexin-V-FITC and PI on a FACSCalibur. 
2.10. In vivo tumorigenesis 
Non-obese diabetic (NOD)/SCID mice (5–6-weeks-old) (NOD.CB17-Prkdcscid/J; Charles River 
Laboratories) were used in this study. All mice were housed in clean cages and maintained 
according to institutional guidelines on animal welfare. Mice were subcutaneously injected 
with 1x106, 105, 104 and 103 cells (n=3, each dose). Mice were followed up for 1 month to detect 
tumors. 
2.11. Statistical analysis 
All experiments were performed in triplicate. A value of P ≤ 0.05 was considered significant. 
Data were analyzed using Statgraphics v 7.0 software (Statgraphics Graphics System, 
Warrenton, VA). 
3. Results 
3.1. Primary culture 
The study was carried out to primary culture five tumors from five patients. There were 3/5 
samples that outgrew cells (Fig. 1A). These cells from the three samples were propagated 
until 80% confluence. In almost all samples, epithelial-like cells appeared before 
mesenchymal-like cells, which spread out from tumor fragments from day 5. Mesenchymal-
like cells usually appeared at day 20. Then, cells proliferated rapidly and formed colonies. 
At this time, two cell shapes were mostly observed in the primary culture (Fig. 1B). These 
were epithelial-like cells with a bean shape and large nucleus, and mesenchymal-like cells 
with a small nucleus and elongated shape. Cells were subcultured once to expand enough 
cells for further experiments. The primary cells from these samples were used in both single-
cell sorting and CD44+CD24-/dim-based cell sorting.  
 
Figure 1. Primary breast cells derived from malignant tumors. (A) Primary cells began to migrate from 
tumors. (B) Primary cells rapidly proliferated with two main shapes indicating stromal and epithelial-
like cells. (C) Cell populations were subcultured for a second passage and cultured in DMEM/F12 
supplemented with 10% FBS.  
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3.2. Single cell-based culture, cell selection and EMT  
Primary cells were individually sorted into the wells of 96-well plates. A total of 2880 wells 
were used for one primary cell population. Single cells were cultured in M171 medium 
containing MEGS for 2 weeks. There were 14.67±5.13 colonies formed per 96-well plate. 
Single cells in other wells did not proliferate or died (n=3). Similarly to primary culture, 
there were two kinds of cell clones. One kind of cell clone was epithelial-like, and the other 
was mesenchymal-like. To enrich mesenchymal-like cells and eliminate epithelial-like cells, 
we changed the medium from M171 medium containing MEGS to DMEM/F12 
supplemented with FBS that was suitable for mesenchymal-like cells. After all epithelial-like 
cell clones died in 24 h, mesenchymal-like cell clones continued to expand to 70–80% 
confluence and were then subcultured. From one sample, 6.33±3.06 mesenchymal-like cell 
clones were derived per 96-well plate (Fig. 1C). These cell clones were subcultured 
continuously for three to five passages to identify the cell clone with the earliest EMT. At the 
third passage, EMT began to occur in some cell clones. These early EMT cell clones were 
considered as BCSCs. EMT occurred randomly in wells, in which some cells changed shape 
from mesenchymal (Fig. 2A) to epithelial (Fig 2. B). This process continued until all cells 
showed epithelial-like shapes (Fig. 2C). We randomly selected one cell clone to analyze the 
characteristics of BCSCs. These procedures were performed similarly for all three samples.  
 
Figure 2. EMT of primary cells. Nearly 100% of cells exhibited a mesenchymal-like shape (A) when 
cultured in DMEM/F12 supplemented with 10% FBS. EMT of some cells (B) formed an islet of epithelial-
like cells. Transitioned cells rapidly proliferated as condensed colonies (C).  
3.3. Immunophenotype, rhodamine 123 efflux and mammosphere formation 
We randomly selected three cell clones from the three samples to analyze the 
immunophenotype, rhodamine 123 efflux and mammosphere formation. The results are 
shown in Fig. 3. BCSC candidates showed a highly homogenous CD44+CD24- phenotype 
(Fig. 3A) with more than 98% positive (98.82±0.72%) (n=3). These cell clones also contained a 
subpopulation (SP- Rhodamine 123 efflux phenotype) that showed more than 66.64±8.51% 
(n=3) (Fig. 3B). In addition, cell clones could form mammospheres when cultured in serum-
free medium (Fig. 3C). Compared with BCSCs from CD44+CD24-/dim cell sorting, the cell 
population was only 90.10±4.12% CD24- and 8.19±3.38% CD24dim (Fig. 3D). Notably, 
CD44+CD24-/dim-sorted BCSCs contained a smaller SP than single-cell sorted BCSCs 
(34.56±3.48% vs. 66.64±8.51%) (Fig. 3E). However, the two kinds of BCSCs strongly exhibited 
mammosphere formation (Fig. 3F).  
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Figure 3. Flow cytometric analyses of immunophenotype and rhodamine 123 efflux. Cell clones 
exhibited the characteristics of BCSCs with near 100% CD44+CD24- (A), and were more than 50% SP-
positive (D). Marker expression and the SP decreased in CD44+CD24-/dim-sorted cells. (D; E). However, 
both types of sorted cells could form mammospheres in serum-free medium (C, F).  
 
Figure 4. Doxorubicin resistance and the cell cycle of BCSCs isolated by CD44+CD24--sorting and 
single-cell sorting. At 3 μg/ml doxorubicin, BCSCs obtained from single-cell sorting did not undergo 
apoptosis (A), whereas apoptosis was observed among CD44+CD24- BCSCs (B). However, the cell cycles 
of these two populations were not significantly different (C–D).  
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3.4. Doxorubicin resistance and the cell cycle 
BCSCs sorted by two strategies were evaluated in this study. BCSCs from single-cell sorting 
could resist doxorubicin more than CD44+CD24-/dim-sorted BCSCs. At 0 and 1 μg/ml 
doxorubicin, cells did not undergo apoptosis. However, at 3 μg/ml doxorubicin, no BCSCs 
underwent apoptosis from single-cell sorting, but there were 2.54±1.29% apoptotic CD44+CD24-
/dim BCSCs (Fig. 4A, B). Although these results showed that there was no significant different 
between BCSCs obtained from single-cell sorting and CD44+CD24-/dim-sorting (Fig. 4C, D).  
3.5. In vivo tumor formation 
Tumorigenicity is an essential characteristic of cancer stem cells. In almost all studies, tumor 
formation at a low number of injected cells is considered as the gold standard for cancer stem 
cell confirmation. In this study, we injected 1×103, 104 and 105 cells into the mammary pad of 
NOD/SCID mice. At 1×103 cells per mouse, BCSCs were able to form tumors (Fig. 5A, B). To  
 
Figure 5. Tumor formation in NOD/SCID mice after injection of 1×103 BCSCs. Tumors formed 
subcutaneously (A) at sizes from 5×6 mm (B), which were analyzed histochemically by HE staining (C).  
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confirm the histopathology of tumors, 10 μm tumor sections were stained with hematoxylin-
eosin (HE). As shown in Figure 5C, tumors exhibited cancer cells with large nuclei. This 
result was similar to that of BCSCs from CD44+CD24-/dim-sorting in our previous studies [41]; 
[42]; [43].  
4. Discussion 
BCSCs are the origin of breast tumors. Thus far, the aim of many studies has been BCSC 
targeting. Recently, preclinical trials have demonstrated that agents targeting BCSCs are 
more effective than those targeting tumor cells. In all BCSC-based therapies, BCSCs are 
important for tumor targeting. However, the procedures used to isolate BCSCs are 
complicated and time consuming. Moreover, all present protocols obtain heterogenous 
populations of BCSCs. Indeed, sorting CD44+CD24- cells, a population considered as 
BCSCs, can express various levels of CD44 and CD24. SPs are also considered as BCSCs, but 
only a subpopulation show a CD44+CD24- phenotype. Thus, the aim of this study was to 
establish a new protocol to isolate homogenous BCSCs.  
Similar to other techniques, our technique also cultured primary cells from malignant 
tumors as a first step. We successfully cultured 3/5 samples under this condition. Cells 
rapidly expanded around tumor fragments after 2 weeks. Various cell types appeared in 
primary culture, including mainly epithelial-like and mesenchymal-like cells. These results 
were consistent with our previous studies [41]; [42]. The primary cell population may 
contain at least six cell types including fibroblasts, mammary epithelial cells, mammary 
epithelial stem cells, breast cancer stem cells, breast cancer cells and stromal cells. To isolate 
homogenous BCSCs at a high purity, we applied single-cell sorting to individually isolate 
single cells in the wells of 96-well plates. For each sample, we sorted single cells into 2880 
wells in 30 plates. From such a plate, we derived 14.67±5.13 cell clones, while other cells 
could not proliferate or died. Using this method, we can select cells that rapidly proliferate 
and survive when cultured alone. Indeed, normal cells and differentiated cells hardly 
proliferate when seeded as single cells. We considered that BCSCs existed among these 
clones. By changing the medium from M171 medium containing MEGS to DMEM/F12 
supplemented with 10% FBS to select mesenchymal-like cell clones, all cell clones with an 
epithelial phenotype died and cell clones with a mesenchymal phenotype survived and 
proliferated. 
There were 6.33±3.06 surviving cell clones per plate, with a mesenchymal-like shape. They 
were continuously subcultured for three to five passages, and cell clones that underwent the 
earliest EMT were chosen for further study. The results showed that cell clones will the 
earliest EMT occurred at the third passage. EMT resulted in cells spreading out to form an 
area with epithelial-like cells among mesenchymal-like cells. After 72 h, all cells transitioned 
into epithelial cells. We randomly selected three cell clones from a sample to analyze the 
characteristics of BCSCs. All three cell clones after EMT showed the properties of BCSCs. 
The cell population exhibited the common CD44+CD24- phenotype of BCSCs at 
98.82±0.72%. This population was used to evaluate the SP by rhodamine 123 efflux. The 
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results showed that the SP was CD44+CD24-/dim. To assess the multidrug-resistance 
property, we checked and compared with two other techniques, we recognized that BCSCs 
from single-cell sorting with higher antitumor drug resistance but the same tumor formation 
in NOD/SCID mice compared with CD44+CD24-/dim-sorting.  
Single-cell sorting combined with subculture to isolate EMT cell clones exhibited several 
benefits for selection of BCSCs. Indeed, single-cell cloning is considered as the best 
technique for selection of a homogenous cell population. This technique is popular for cell 
cloning of hybridomas for monoclonal antibody production. However, in monoclonal 
antibody production, almost all studies use limited dilution or ring/syringe isolation. These 
two techniques have some limitations; particularly the low efficiency in dilution to obtain 
single cells in each well and it is laborious, time-consuming and uneconomical to screen 
samples with a low concentration of desired cells. Using the index sorting of the FACSJazz, 
it is easy to seed one cell in each well of 96-well plates. Single-cell sorting offers a new tool to 
efficiently and rapidly perform cell cloning.  
In the next step, we cultured single cells to obtain cell clones for subculture. In mammalian 
cell culture, single-cell culture is usually suitable for transformed cells and immortal cell 
lines. Normal cells usually undergo apoptosis after 50±10 divisions because of the Hayflick 
limitation [27]. Thus, single-cell culture is only suitable for immortal cells. Indeed, in our 
study, when primary cells from tumors were individually cultured, some types of non-
immortal cells can be eliminated after culture and subculture. Using single cell-based 
culture and sub-culture, almost all cell clones of stromal, epithelial and breast cancer cells 
can be lost over time. Thus, after three passages, some cell clones survive and can form 
continuous cultures. There were two cell types, namely epithelial-like cells and 
mesenchymal-like cells. We considered that mammary epithelial stem/progenitor cells 
exhibited the epithelial shape and breast cancer stem cells exhibited the mesenchymal shape. 
Mammary epithelial stem cells cannot survive in medium without hydrocortisone and EGF, 
whereas BCSCs do not depend on hydrocortisone or EGF [18]. Moreover, serum can inhibit 
the growth of normal epithelial cells from mammary tumors [17]. To eliminate mammary 
epithelial stem/progenitor cells, we changed the culture medium to DMEM/F12 
supplemented with 10% FBS. After 48 h culture in this new medium, all epithelial-like cell 
clones did not survive, while all mesenchymal-like cell clones survived.  
We propose that at this step, we successfully selected BCSC clones or BCSC-like clones. In 
the next experiment, we selected the strongest BCSC clone. The strongest BCSC clone was 
selected based on the time of EMT. EMT is related to the initiation of metastasis and cancer 
by BCSCs [2]; [52]; [20]; [53]; [48]; [45]; [35]. EMT can result in cells with stem cell properties 
[33]. Notably, Morel et al. (2008) could obtain BCSCs from EMT [37]. In a recent study, Blick 
et al. (2010) determined that EMT occurs together with the CD44+CD24-/dim phenotype of 
BCSCs [6]. Thus, in this study, cell clones that rapidly transitioned from mesenchymal to 
epithelial phenotypes were chosen as the most appropriate BCSC clone. 
However, based on immunophenotypic and rhodamine 123 analyses, we found that BCSCs 
from single-cell sorting might not be homogenous. Indeed, a few cells did not exhibit the 
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CD44+CD24- immunophenotype or SP phenotype, indicating that BCSCs had differentiated 
into other cell types during proliferation. Such differentiation may be induced by medium 
containing serum. Some studies show that serum can induction differentiation of BCSCs 
[47]; [23]. Moreover, single cell-based culture easily induces differentiation [36]. Thus, 
single-cell sorting can obtain a pure population of BCSCs that must be maintained in a 
suitable medium to inhibit spontaneous differentiation.  
5. Conclusion 
Single-cell sorting is suitable for isolation of BCSCs to obtain a homogenous population for 
further experimentation and BCSC-targeting therapies. BCSCs obtained by this technique 
exhibit high purity, high resistance to doxorubicin, and form tumors in NOD/SCID mice at a 
low cell number. Compared with CD44+CD24- sorting, mammosphere culture and SP-based 
sorting, single-cell sorting in combination with subculture enables selection of EMT cell 
clones that give rise to a BCSC population with advantages such a homogenous population, 
higher doxorubicin resistance and mammosphere formation at high levels. However, 
spontaneous differentiation in culture is a problem that needs to be addressed. Single-cell 
sorting offers a new technique to detect and isolate BCSCs as well as other cancer stem cell 
types.  
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